SUPERNUS PHARMACEUTICALS, INC. (SUPN)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, SUPERNUS PHARMACEUTICALS, INC. reported revenue of $718.95M, up 8.6% from the prior year. The company ran a net loss, with a net margin of -5.4%. It held $1.45B in total assets against $390.93M in total liabilities.
Key ratios (FY2025)
-8.7%
Operating margin
-5.4%
Net margin
-3.6%
Return on equity
+8.6%
Revenue growth (YoY)
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $718.95M | $661.82M | $607.52M | $667.24M | $579.77M | $520.40M | $392.75M | $408.90M | — | — |
| Cost of Revenue | $74.56M | $77.91M | $83.78M | $87.22M | — | $52.46M | $16.66M | $15.36M | $15.21M | $11.99M |
| Operating Income | -$62.28M | $81.67M | -$5.27M | $46.12M | $86.03M | $173.70M | $148.57M | $144.44M | $99.54M | $54.22M |
| Net Income | -$38.55M | $73.86M | $1.32M | $60.71M | $53.42M | $126.95M | $113.06M | $110.99M | $57.28M | $91.22M |
| EPS (Diluted) | $-0.68 | $1.32 | $0.02 | $1.04 | $0.98 | $2.36 | $2.10 | $2.05 | $1.08 | $1.76 |
| Total Assets | $1.45B | $1.37B | $1.28B | $1.70B | $1.69B | $1.50B | $1.16B | $977.81M | $424.46M | $309.57M |
| Total Liabilities | $390.93M | $332.34M | $356.16M | $816.30M | $873.30M | $759.24M | $564.85M | $524.79M | $156.98M | $117.81M |
| Shareholders' Equity | $1.06B | $1.04B | $921.52M | $886.20M | $815.85M | $744.86M | $595.43M | $453.02M | $267.48M | $191.75M |
| Cash & Equivalents | $128.45M | $69.33M | $75.05M | $93.12M | $203.43M | $288.64M | $181.38M | $192.25M | $100.30M | $66.40M |
| Operating Cash Flow | $47.33M | $171.95M | $111.08M | $116.83M | $127.13M | $138.40M | $143.13M | $128.99M | $114.64M | $66.81M |
| Capital Expenditures | $1.34M | $725.0K | $551.0K | $412.0K | — | $3.45M | $2.74M | $844.0K | $2.03M | $1.60M |
| Shares Outstanding | 56.45M | 55.96M | 55.51M | 61.68M | 54.36M | 53.69M | 53.82M | 54.10M | 53.30M | 51.71M |